Table 1.
Cohort demographics (n = 49).
| Characteristic | Number (%)/Median [Range] | |
|---|---|---|
| Age at diagnosis (years) | 53.5 [14–80] | |
| Age at Asciminib (years) | 59 [23–88] | |
| Gender | ||
| Male | 27 (55%) | |
| Female | 22 (45%) | |
| Disease phase at diagnosis | ||
| Chronic | 48 (98%) | |
| Accelerated | 1 (2%) | |
| Disease phase at asciminib initiation | ||
| Chronic | 49 (100%) | |
| ACA at diagnosis | ||
| No | 36 (73%) | |
| Yes | 3 (6%) | |
| Unknown | 10 (20%) | |
| ELTS score at diagnosis | ||
| Low | 16 (33%) | |
| Intermediate | 9 (18%) | |
| High | 4 (8%) | |
| Missing | 20 (41%) | |
| Transcript type | ||
| e13a2 | 19 (39%) | |
| e14a2 | 12 (24%) | |
| e13a2/e14a2 | 9 (18%) | |
| Unknown, (non-rare) | 8 (16%) | |
| e19a2 | 1 (2%) | |
| Time since diagnosis (months) | 73 [11–386] | |
| Number of prior TKIs (median) | 4 [2–5] | |
| Last TKI | ||
| Imatinib | 1 (2%) | |
| Bosutinib | 17 (35%) | |
| Dasatinib | 5 (10%) | |
| Nilotinib | 4 (8%) | |
| Ponatinib | 22 (45%) | |
| Prior ponatinib use | 29 (59%) | |
| Ponatinib resistant | 9 (18%) | |
| Reason for stopping last TKI | ||
| Resistance | 17 (35%) | |
| Intolerance | 32 (65%) | |
| Achieved CCyR to at least 1 previous line of therapy | 35 (71%) | |
| BSNV (History) | ||
| Any | 21 (43%) | |
| T315I | 11 (22%) | |
| Non-T315I-BSNV all | 12 (24%) | |
| Non-T315I-BSNV clinically significant | 10 (20%) | |
ACA additional chromosomal abnormalities, ELTS Eutos long-term survival, TKI tyrosine kinase inhibitor, CCyR complete cytogenetic response, BSNV, BCR::ABL1 single nucleotide variants.